Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE
DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) has provided program updates for Fragile X syndrome (FXS), autism spectrum disorder (ASD), 22q11.2 deletion syndrome (22q) and developmental and epileptic encephalopathies …
Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE Read More